Referanser

Tilbake til artikkelen Førstegangspsykose og suicidalitet

• Addington J., Williams, J., Young, J, Addington, D. (2004). Suicidal behaviour in early psychosis. Acta Psychiatrica Scandinavica, 109, 116-120.
• Amador, X.F., Friedman, J.H., Kasapis, C., Yale, S.A et al (1996). Suicidal behaviour in schizophrenia and its relationship to awareness of illness. American Journal of Psychiatry, 153, 1185-1188.
• Amador, X.F.& Gorman, J.M. (1998). Psychopathological domains and insight in schizophrenia. Psychiatric clinics of North America, 21, 1, 27 -42.
• Bentsen, H. (1999). Selvmord ved schizofreni. Suicidologi, 1.
• Bilder, R.M., Goldman R.S., Robinson, D., et al (2000). Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates. American Journal of Psychiatry, 157, 549-559.
• Binder, J., Albus, M., Hubman, W., Scherer J., et al (1998). Neuropsychological impairment and psychopathology in forst-episode schizophrenic patients related to the early course of illness. European Archives of Psychiatry and Clinical Neuroscience, 248, 70-77.
• Brown, S. (2000). Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212-17.
• Caldwell, C.B., Gottesman I.I. (1990). Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophrenia Bulletin, 16, 571-88.
• Caldwell, C.B., Gottesman I.I. (1992). Schizophrenia – A high-risk factor for suicide: Clues to risk reduction. Suicide and Life-threatening Behaviour, 22, 4, 479-93.
• Caldwell, T.M., & Jorm, A.F. (2000). Mental health nurses’ beliefs about interventions for schizophrenia and depression: a comparison with psychiatrists and the public. Australian and New Zealand Journal of Psychiatry, 34, 4, 602-11.
• Caspi, A., Reichenberg A., Weiser, M., Rabinowitz, J. et al (2003). Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophrenia Research, 1922, 1-8.
• David, A.S. (1990). Insight and psychosis. British Journal of Psychiatry, 156, 798-808.
• De Hert, M., McKenzie, K., Peuskens, J. (1999) Risk factors for suicide in young people suffering from schizophrenia: a long-term follow up study. Schizophrenia research, 47, 127-134.
• Erlenmeyer-Kimling, L., Rock, D., Roberts, S.A, Janal, M. et al (2000). Attention, memory and motor skills as childhood predictors of schizophrenia-related psychoses: The New York high-risk project. American Journal of Psychiatry, 157, 1416-1422.
• Fennig, S. Everett, E., Bromet, E.J., Jandorf, L., Fennig, S.R., Tanenberg-Krant, M., Craig, J.C. (1996). Insight in first-admission psychotic patients. Schizophrenia research, 22, 3, 257-63.
• Fenton, W.S. (2000). Depression, suicide, and suicide prevention in schizophrenia. Suicide and Life-Treatening Behavior, 31, 34-49.
• Green, M.F., Kern, R.S., Braff, D.L. Mintz J. (2000). Neurocognitive deficits and functional outcome in schizophrenia:are we measuring the “right stuff”? Schizophrenia Bulletin, 26, 1, 119-36.
• Harkavy-Friedman, J.M., Restifo, K., Kaufmann, C.A., Amador, X.F., Gorman, J.M. (1999). Suicidal behavior in schizophrenia: Characteristics of individuals who had and had not attempted suicide. American journal of Psychiatry, 156, 1276-78.
• Hillert, A., Sandmann, J., Ehmig, S.C., Sobota, K., et al (1999). The general public’s cognitive and emotional perception of mental illness:an alternativ to attitude-research.
• I J.Guimon, W.Fischer, N. Sartorius (red) The Image of Madness: The Public facing mental illness and psychiatric treatment. Basel:Karger.
• Hyler, S.E., Gabbard, G.O., Schneider, L. (1991). Homicidal maniacs and narcissistic parasites: stigmatizing of mentally ill persons in the movies. Hospital and Community Psychiatry, 42, 1044-1048.
• Jorgensen, P. (1995). Recovery and insight in schizophrenia. Acta psychiatrica Scandinavica, 92, 6, 436-40.
• Jorm, A.F., Korten, A.E., Jacomb, P.A., Christensen H., et al. (1997). Mental health literacy: a survey of the public’s ability to recognize mental disorders and their beliefs about the effectiveness of treatment. Medical Journal of Australia, 166, 182-186.
• Kaplan K.J. & Harrow, M. (1999). Psychosis and functioning as risk factors for later suicidal activity among schizophrenia and schizoaffective patients: a disease-based interactive model. Suicide and Life-threatening Behaviour, 29, 1, 10 -24.
• Kim, C.H., Jayathilake, K., Meltzer, H.Y. (2003). Hopelessness, neurocognitive function and insight in schizophrenia: Relationship to suicidal behaviour. Schizophrenia Research, 60, 71-80.
• Lewis, L. (2004). Mourning, insight, and reduction of suicide risk in schizophrenia. Bulletin of the Menninger Clinic, 68, 3, 231-244.
• Melle, I., Johannessen, J.O., Friis, S., Haahr, U. (in press). Early detection of first episode psychosis reduces suicide attempts up to initial treatment. American Journal Psychiatry.
• Mintz, A., Dobson K.S., Romney, D.M. (2004). Insight in schizophrenia: a meta-analysis. Schizophrenia research, 61, 75-88.
• Nangle, J.E., Clarke, S., Donohoe, G., Schwaiger, S., et al (2005). Neurocognition and Suicidal behaviour in an irish population with major psychotic disorders. International Congress on Schizophrenia Research.
• Nordentoft, M., Jeppesen, P., Abel, M., Kassow, P., et al (2002). OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis. British Journal of Psychiatry, 181 suppl.43, 98 – 106.
• Palmer, B.A., Pankratz, V.S., Bostewick, J.M. (2005). The lifetime risk of suicid in schizophrenia. Archives of general psychiatry, 62, 247-53.
• Pekkela, E & Merinder, L. (2005). Psychoeducation for schizophrenia. Cochrane Database System Review, 2.
• Pompili, M., Ruberto, A., Kotzalidis, G.D., Girardi, P., Tatarelli, R. (2004). Suicide and awareness of ollness in schizophrenia: An overview. Bulletin of the Menninger Clinic, 68, 4, 297-318.
• Potkin, S.G., Anand, R., Alphs, L., Fleming, K. (2002). Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicide. Schizophrenia research, 59, 59-66.
• Power, P.J.R., Bell, R.J., Mills, R., Herrman-Doig, T. et al (2003) Suicide prevention in first-episode psychosis: the development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis. Australian and New Zealand Journal of Psychiatry, 37, 314-420.
• Priest, R.G., Vize, C., Roberts, A., Tyle, A. (1996). Lay people’s attitudes to treatment of depression: results of opinion poll for Defeat Depression Campaign just before its launch. British Medical Journal, 313, 858-859.
• Quillams, L. & Addington, J (2003). Insight, knowledge and beliefs about illness in first-episode psychosis. Canadian Journal of Psychiatry, 48, 5, 350.
• Regier, D.A., Hirschfeld, R.M.A., Goodwin, F.K., Burke, J.D., Lazar, J.B., Judd, L.L. (1988). The NIMH depression, awareness, recognition, and treatment program: structure, aims and scientific basis. American Journal of Psychiatry, 145, 1351-1357.
• Rissmiller, D.J., Ranieri, W.F., Rissmiller, F., Hogate, P. (1994). Factors complicating cost containment in the treatment of suicidal patients. Hospital and Community Psychiatry, 45, 782-88.
• Rund, B.R. (2002). Nevrokognitive forstyrrelser ved schizofreni. Tidsskriftet for den norske lægeforening, 30, 122, 2019-22.
• Rund, B.R., Egeland, J., Sundet, K., Asbjørnsen, A., et al (2004). Early visual information processing in schizophrenia compared to recurrent depression. Schizophrenia research, 68, 111-118.
• Schwartz, R.C. (2000). Insight and suicidality in schizophrenia: An analysis of 17 consecutive suicides. Schizophrenia Bulletin, 188, 533-542.
• Schwartz, R.C., & Petersen, S. (1999). The relationship between insight and suicidality among patients with schizophrenia. Journal of Nervous and Mental Disease, 187, 376-378.
• Siris, S.G. (2001). Suicide and schizophrenia. Journal of Psychopharmacology, 15, 2, 127-35.
• Steblaj, A., Tavcar, R., Dernovsek, M.Z. (1999). Predictors of suicide in psychiatric hospital. Acta Psychiatrica Scandinavica, 100, 383-388.
• Tarrier, N., Barrowclough, C., Andrews, B., Gregg, L. (2004). Risk of non-fatal suicide ideation and behaviour in recent onset schizophrenia. Social psychiatry and psychiatric epidemiology, 39, 927-37.
• Thompson, K.N., McGorry, P.D., Harrigan, S.M. (2001). Reduced awareness of illness in first-episode psychosis. Comparative Psychiatry, 42, 6, 498-503.
• Turkington, D., Kingdon D., Turner T. (2002). Effectiveness of a brief-cognitive-behavioural therapy intervention in the treatment of schizophrenia. British Journal og psychiatry, 180, 523-527.
• Wolf, G., Pathare, S. Craig, T., Leff, J. (1996). Community knowledge of mental illness and reaction to mentally ill people. British Journal of Psychiatry, 168, 191-198.
• Young A.S., Neuchterlein K.H., Mintz, J., Ventura, J., et al (1998). Suicidal ideation and suicide attemptes in recent-onset Schizophrenia. Schizophrenia Bulletin, 24, 4 629-34.

Aktuelt på AstraZeneca.no nå

12.04.10 Gratis e-læringskurs om Astma Lær mer om symptomer, bakgrunn og behandling av astma. Kurset gir en generell beskrivelse av lungene og forteller deretter om astma som sykdom og om hva som skjer ved astmaanfall samt hvilke tester legen kan benytte for å påvise astma. Kurset avsluttes med informasjon om hvordan du kan unngå astmautløsende faktorer og om hvilke alternativer som finnes for behandling av astma. Start kurset

28.05.10: Astma og allergi i ferietiden Som astmatiker eller allergiker er det mye man bør passe på. Dette gjelder også når man skal på ferie. Her er noen reisetips.

Aktuelle nyheter om AstraZeneca

28.05.2010 AstraZeneca flytter til nye lokaler på Helsfyr Mandag d. 31 mai vil AstraZeneca Norge være på plass i nye lokaler på Helsfyr. Besøksadressen er: Innspurten 15, 0663 Oslo. Ny post adresse er: Postboks 6050, Etterstad, 0601 OSLO 04.05.2009 AstraZeneca oppretter et nytt nordisk markedsføringsselskap - styrket kompetanse med fortsatt sterk lokal kundestøtte. AstraZeneca vil konsentrere sine markedsføringsressurser i Danmark, Finland, Norge og Sverige i ett nytt nordisk markedsføringsselskap. Det nye selskapet vil være basert i Södertälje i Sverige. Det nordiske markedsselskapet vil være ansvarlig for strategiske og administrative oppgaver, mens direkte kunderelasjoner forblir lokale. I alle nordiske land vil det være en sterk lokal kundeorganisasjon for å sikre at kundene får kontinuerlig service av høy kvalitet. Les mer.

Andre norske nettsteder fra AstraZeneca

AstraZeneca har flere nettsteder beregnet både på det generelle publikum og på spesielle faggrupper.